Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 5, 1997, Pages 1059-1068

  Formenti, Silvia C ^a   Dunnington, Gary ^a   Uzieli, Beatrice ^a   Lenz, Heinz ^a   Keren Rosenberg, S ^a   Silberman, Howard ^a   Spicer, Darcy ^a   Denk, Mary ^a   Leichman, Gail ^a   Groshen, Susan ^a   Watkins, Kristy ^a   Muggia, Franco ^a   Florentine, Barbara ^a   Press, Michael ^a   Danenberg, Kathleen ^a   Danenberg, Peter ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

5 Fluorouracil and radiation; Locally advanced breast cancer; P53; Pathological response

Indexed keywords

FLUOROURACIL; HORMONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER RADIOTHERAPY; CELLULITIS; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MASTECTOMY; MUCOSA INFLAMMATION; PRIORITY JOURNAL;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED;

EID: 0030657740     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00506-3     Document Type: Article

References (54)

1. Allred, D. C.; Clark, G. M.; Elledge, R.; Fuqua, S. A. W.; Brown, R. W.; Chamness, G. C.; Osborne, J. C. J. K.; McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 85:200-206; 1993.
2. Atkins, H. L.; Horrigan, W. D. Treatment of locally advanced carcinoma of the breast with roentgen therapy and simple mastectomy. AJR 85:860-864; 1961.
3. Bagshaw, M. A. Possible role of potentiators in radiation therapy. AJR 85:822-833; 1961.
4. Bergh, J.; Norberg, T.; Sjorgren, S.; Lindgren, A.; Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant therapy and radiotherapy. Nat. Med. 1:1029-1123; 1995.
5. Bonadonna, G.; Veronesi, U.; Brambilla, C.; Ferrari, L.; Luini, A.; Greco, M.; Bartoli, C.; Coopmans de Yoldi, G.; Zucali, R.; Rilke, F.; Andreola, S.; Silvestrini, R.; Di Fronzo, G.; Valagussa, P. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82:1539-1545; 1990.
6. Bristow, R. G.; Benchimol, S.; Hill, R. p53 Protein expression or protein function? Re: Awwad et al: Int. J. Radiat. Oncol. Biol. Phys. 34:323-332; 1996.
7. Byfield, J. E.; Calabro-Jones, P.; Klisak, I.; Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and x-rays. Int. J. Radiat. Oncol. Biol. Phys. 8:1923-1933; 1982.
8. Cattoretti, G.; Rilke, F.; Andreola, S.; D'Amato, L.; Delia D. p53 expression in breast cancer. Int. J. Cancer. 41:178-183; 1988.
9. Cocconi, G.; DiBlasio, B.; Alberti, G.; Bisagni, G.; Botti, E.; Peracchia, G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res. Treat. 4:309-313; 1984.
10. Dorr, F. A.; Bader, J.; Friedman, M. A. Locally advanced breast cancer current status and future directions. Int. J. Radiat. Oncol. Biol. Phys. 16:775-784; 1989.
11. Elledge, R. M.; Fuqua, S. A. W.; Clark, G. M.; Pujol, P.; Allred, D. C.; McGuire, W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treat. 26:225-235; 1993.
12. Feldman, L.; Hortobagyi, G.; Buzdar, A.; Ames, F.; Blumenschein, G. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46:2578-2581; 1986.
13. Fletcher, G. H. Clinical dose-response curves of human malignant epithelial tumors. Br. J. Radiol. 46:1; 1973.
14. Fracchia, A. A.; Evans, J. F.; Eisenberg, B. I. Stage III carcinoma of the breast: A detailed analysis. Ann. Surg. 192: 705-710; 1992.
15. Frebourg, T.; Friend, S. H. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J. Natl. Cancer Inst. 85:1554-1557; 1993.
16. Hansen, R.; Quebbeman, E.; Beatty, P.; Ritch, P.; Anderson, T.; Jenkins, D.; Frick, J.; Ausman, R. Continuous 5-Fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Treat. Res. 10:145-149; 1987.
17. Harris, J. R.; Sawicka J.; Gelman R. Management of locally advanced carcinoma of the breast by primary radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 9:345-349; 1983.
18. Hatfield, A. K.; Johnson, P. A.; Egner, J. R.; Long, C. A. Long term continuous 5-Fluorouracil (5-FU) infusion in the treatment of far advanced metastatic breast carcinoma. The Carle Cancer Center CCOP, Urbana, Illinois 61801. Proc. ASCO 8:35; 1989.
19. Heidelberger, C.; Greisbach, L.; Montag, B. J.; Cruz, D.; Schnitzner, R. J.; Grunberg, E. Studies in fluorinated pyrimidines. II. Effects of transplanted tumor. Cancer Res. 18:305-317; 1958.
20. Herskovic, A.; Martz, K.; Al-Sarraf, M.; Leichman, L.; Brindle, J.; Vaitkevicius, V.; Cooper, J.; Byhardt, R.; Davis, L.; Emami, B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326:1593-1598; 1992.
21. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 Mutations in human cancers. Science 253:49-53; 1991.
22. Hortobagyi, G. N. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74:416-423; 1994.
23. Hortobagyi, G. N.; Blumenschein, G. R.; Spanos, W.; Montague, E. D.; Buzdar, A. U.; Yap, H. Y.; Sclell, F. Multimodal treatment of locoregionally advanced breast cancer. Cancer 51:763-768; 1983.
24. Hortobagyi, G. N.; Buzdar, A. U. Locally advanced breast cancer: A review including the M.D. Anderson experience. In: Ragaz, J.; Ariel, I. M., eds. High-risk breast cancer - Therapy. Berlin: Springer Verlag; 1991:382-415.
25. Huan, S.; Pazdu, R.; Singhakowinta, A.; Samal, B.; Vaitkevicius, V. K. Cancer 63:419-422; 1989.
26. Isola, J.; Visakorpi, T.; Holli, K.; Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst. 84:1109-1114; 1992.
27. Jabboury, K.; Holmes, F. A.; Hortobagyi, G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64:793-797; 1989.
28. Jacquillat, C.; Baillet, F.; Weil, M.; Auclerc, G.; Housset, M.; Auclerc, M. F.; Sellami, M.; Jindani, A.; Thill, L.; Soubrane, C.; Khayat, D. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 61:1977-1982; 1988.
29. Kovach, J. S.; Hartmann, A.; Blaszyk, H.; Cunningham, J.; Schaid, D.; Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 93:1093-1096; 1996.
30. Lane, D. P. p53, guardian of the genome. Nature 358:15-16; 1992.
31. Lawrence, T. S.; Davis, M. A.; Maybaum, J. Dependence of 5-fluorourracil-mediated radiosensitization on DNA-directed effects. Int. J. Radiat. Oncol. Biol. Phys. 29:519-523; 1994.
32. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene. Nature 351:453-456; 1991.
33. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967; 1993.
34. Mazars, R.; Spinardi, L.; BenCheikh, M.; Simony-Lafontaine, J.; Jeanteur, P.; Theillet, C. p53 Mutations occur in aggressive breast cancer. Cancer Res. 52:3918-3923; 1992.
35. McGinn, C. J.; Kinsella, T. J. The clinical rationale for S-phase radiosensitization in human tumors. Curr. Problems Cancer 17:273-321; 1993.
36. McGinn, C. J.; Miller, E. M.; Lindstrom, M. J.; Kunugi, K. A.; Johnston, P. G.; Kinsella, T. J. The role of cell cycle redistribution in radiosensitization: Implications regarding mechanism of fluorodeoxyuridine radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 30:851-859; 1994.
37. Mulder, J. W. R.; Offerhaus, G. J. A.; Vogelstein, B.; Hamilton, S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 172:5-12; 1994.
38. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450; 1990.
39. O'Connell, M. J.; Martenson, J. A.; Wieand, H. S.; Krook, J. E.; MacDonald, J. S.; Haller, D. G.; Mayer, R. J.; Gunderson, L. L.; Rich, T. A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Eng. J. Med. 331: 502-507; 1994.
40. Pierce, L.; Adler, D.; Helvie, M.; Lichter, A.; Merajver, S. The use of mammography in breast preservation in locally ad-vanced breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 34: 571-577; 1996.
41. ROTG. Acute radiation morbidity score criteria. In: Perez, C. A.; Brady, L. W., eds. Principles and practice of radiation oncology. Philadelphia, PA: Lippincott Co; 1992:51-53.
42. Schwartz, G. F.; Birchansky, C. A.; Komarnicky, L. T.; Mansfield, C. M.; Cantor, R. L; Biermann, W. A.; Felling, F. M.; McFarlane, J. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369; 1994.
43. Segel, M. C.; Paulus, D. D.; Hortobagyi, G. N. Advanced primary breast cancer: Assessment of mammography of response to induction chemotherapy. Radiology 169:49-54; 1988.
44. Singletary, S. E.; McNeese, M. D.; Hortobagyi, G. N. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69: 2849-2852; 1992.
45. Sischy, B.; Doggett, R. L. S.; Krall, J. M.; Taylor, D. G.; Sause, W. T.; Lipsett, J. A. Seydel, H. G. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: Interim report on Radiation Therapy Oncology Group Study No. 8314. J. Natl. Cancer Inst. 891:850-856; 1989.
46. Sobreoro, A. F.; Aschele, C.; Guglielmi, A. P.; Mori, A. M.; Melioli, G. G.; Rosso, R.; Bertino, J. R. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J. Natl. Cancer Inst. 85:1937-1944; 1993.
47. Szumiel, I. Review: Ionizing radiation-induced cell death. Int. J. Radiat. Biol. 66:329-341; 1994.
48. Thomas, F.; Arriagada, R.; Mouriesse, H: Radical radiotherapy alone in non-operable breast cancer: The major impact of tumor size and histological grade on prognosis. Radiother. Oncol. 13:267; 1988.
49. Thor, A. D.; Moore, D. H.; Edgerton, S. M.; Kawasaki, E.; Reihsaus, E.; Lynch, H. T.; Marcus, J. N.; Schwartz, L.; Chen, L. C; Mayall, B. H.; Smith, H. S. Accumulation of the p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 84:845-855; 1992.
50. Thorlacius, S.; Borresen, A. L.; Eyfjord, J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: A Prognostic Factor. Cancer Res. 53:1637-1641; 1993.
51. Townsend, C. M., Jr.; Abston, S.; Fish, J. C. Surgical adjuvant treatment of locally advanced breast cancer. Ann. Surg. 201: 604-610; 1985.
52. Tsuda, H.; Iwaya, K.; Fukutomi, T.; Hiroshashi, S. p53 Mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn. J. Cancer Res. 84:394-401; 1993.
53. Vietti, T.; Eggerding, F.; Valeriote, F. Combined effect of X-radiation and 5-fluorouracil on survival of transplanted leukemic cells. J. Natl. Cancer Inst. 47:865-870; 1971.
54. Whal, R. L.; Zasadny, K.; Helvie, M.; Hutchins, G.; Weber, B.; Cody, R. Metabolic monitoring of breast cancer chemohormonotherapy using position emission tomography: Initial evaluation. J. Clin. Oncol. 11:2101-2111; 1993.